A staggering 61% of the FDA's budget for overseeing drugs and devices comes directly from the pharmaceutical industry, raising questions about the integrity of oversight. This financial dependency potentially skews the FDA's role as a watchdog, leading to concerns about the influence of profit motives on public health. Exploring international examples reveals alternative approaches to managing pharmaceutical relationships that could improve healthcare outcomes in the U.S.
